Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

Deadline For Submissions Is 23 February

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Stopwatch (shutterstock_157284068)
• Source: Shutterstock

Drug development is a long and arduous process, more likely to fail than not. That is why we hold the Citeline Awards, to honor the remarkable achievements and the efforts made along the way by biopharma companies as well as companies providing services to the industry. Seize the opportunity to bring recognition and raise awareness of your innovative work in research and development.

The deadline for entries is approaching. Entries received before the 23 February deadline carry a $99 fee, which can be applied toward attendance at the event; the fee for late submissions is $199. Guidance on the submission process is available on the Citeline Awards website. All entries are judged by an independent panel of industry experts.

The 12 award categories recognize a range of activities:

  • Excellence in Rare Disease Drug Development
  • Best Use of Artificial Intelligence in Clinical Trials
  • Excellence in Patient Recruitment and Engagement
  • Best Patient-Facing Technology Initiative
  • Best Sponsor-Facing Technology Initiative
  • Most Successful Early Phase Research (Preclinical & Phase I)
  • Champion of Diversity & Inclusion in Clinical Trials
  • Clinical Partnership of the Year
  • Most Innovative Start-Up Company
  • Clinical Research Team of the Year
  • Excellence in Use of Real-World Data/Evidence
  • Clinical Trial Result of the Year (open to pharma and biotech companies only)

The Citeline Awards will be held 8 May at the Westin Boston Seaport District Hotel. Please join us in celebrating the global community of biopharmaceutical R&D!

More from R&D

More from Scrip

Stock Buyback Is Vote Of Confidence From Genmab Board

 
• By 

The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares

Cassava At Crossroads As Simufilam Finally Exits, Stage Left

 

The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.